Radioimmunotherapy (RIT) combines monoclonal antibodies that targetoverexpressed receptors on tumors with α- or β-particle-emittingradionuclides.12 However, only two preclinicalstudies have reported α-particle RIT of HER2-positive BC with 225Ac-labeled trastuzumab. Here, ERBB2 is linked to breast cancer.